{
  "document_id": "HOUSE_OVERSIGHT_028420",
  "filename": "IMAGES-009-HOUSE_OVERSIGHT_028420.txt",
  "text": "v W\n\nproducts.\",\"type\":\"text\"}, {\"identifier\":\" anf-body-\n41\",\"inlineTextStyles\":[{\"range\": {\"length\":258, \"start\":0},\"textstyle\":\" anf-ts-\nI\"}, {\"range\"™: {\"length\":258,\"start\":0},\"textStyle\":\" anf-ts-1\"}],\"layout\":\"default-\nbody\", \"role\":\"body\", \"text\":\"In restricting access to Revlimid and Thalomid, Celgene\nrelied on a federal requirement that the distribution of those drugs be tightly\nregulated because of their dangerous side effects under a program known as Risk\nEvaluation and Mitigation System, or\nREMS.\", \"type\": \"text \"}, {\"components\":[{\"caption\":\"Elaine Kodish, who lives in Los\nAngeles, said she pays $785 a month for Revlimid, a drug produced by Celgene that helps\ntreat her multiple myeloma. Emily Berl for The New York\n\nTimes\", \"captionComponent\": {\"text\":\"Elaine Kodish, who lives in Los Angeles, said she\npays $785 a month for Revlimid, a drug produced by Celgene that helps treat her\n\nmultiple myeloma. Emily Berl for The New York\n\nTimes\"},\"identifier™:\"100000006098034 S5ba8b8041267d\", \"imageIdentifier\"™:\" 32d2f6bc7b8b\ndbJVabad5d6cab07a43\", \"layout\": \"fullbleed-\n\nimage\", \"role\":\"photo\", \"type\":\"scalable image\"}, {\"identifier\":\" anf-caption-\n4\",\"inlineTextsStyles\": [{\"range\":{\"Llength\":34,\"start\":147},\"textStyle\":\"photo-\ncredit\"}],\"layout\":\"default-caption\", \"role\": \"caption\", \"text\":\"Elaine Kodish, who lives\n\nin Los Angeles, said she pays $785 a month for Revlimid, a drug produced by Celgene\nthat helps treat her multiple myeloma. Emily Berl for The New York Times\n\n\",\"type™:\"text\"}],\"identifier\":\" anf-container-3\", \"layout\": \"image-\n\ncontainer\", \"role\":\"container\", \"type\":\"container\"}, {\"identifier\":\" anf-body-\n42\",\"inlineTextStyles\":[{\"range\":{\"length\":111,\"start\":0},\"textsStyle\":\" anf-ts-\ni\"}, {\"range\"™:{\"length\":111,\"start\":0},\"textStyle\":\" anf-ts-1\"}],\"layout\":\"default-\nbody\", \"role\":\"body\", \"text\":\"Congress expressly prohibited drug companies from using\nthese programs to block or delay generic drug\n\napproval.\",\"type\":\"text\"}, {\"identifier\":\" anf-body-\n43\",\"“inlineTextStyles\":[{\"range\":{\"length\":88,\"start\":0},\"textStyle\":\" anf-ts-\n\ni\"}, {\"range\"™:{\"length\":88,\"start\":0},\"textStyle\":\" anf-ts-1\"}],\"layout\":\"default—\n\nbody\", \"role\":\"body\", \"text\":\"Yet, according to three lawsuits filed by generic drug\n\ncompanies, Celgene did just that.\",\"type\":\"text\"}, {\"identifier\":\" anf-body-\n44\",\"“inlineTextStyles\":[{\"range\": {\"length\":315, \"start\":0},\"textsStyle\":\" anf-ts-\ni™}, {\"range™:{\"length\":315,\"start\":0},\"textStyle\":\" anf-ts-1\"}],\"layout\":\"default-\n\nbody\", \"role\":\"body\", \"text\":\"It began with a simple refusal to distribute samples of\ntheir drugs, citing REMS and demanding that generic drug companies provide written\nconfirmation from the F.D.A. permitting Celgene to provide drug samples. In the case of\nMylan, one of the generic drug companies that sued Celgene, this process took 19\n\nmonths.\", \"type\": \"text\"}, {\"identifier\":\" anf-body-\n45\",\"inlineTextStyles\":[{\"range\": {\"length\":251, \"start\":0},\"textstyle\":\" anf-ts-\nI\"}, {\"range\"™:{\"length\":251,\"start\":0},\"textStyle\":\"_ anf-ts-1\"}],\"layout\":\"default—\n\nbody\", \"role\": \"body\", \"text\":\"After the generic companies sent approval from the F.D.A.,\nCelgene would request more information before agreeing to distribute the drug. But\naccording to court documents in the Mylan case, these requests were laborious,\n\nirrelevant and time consuming.\",\"type™:\"text\"}, {\"identifier\":\" anf-body-\n46\",\"inlineTextStyles\": [{\"range\": {\"length\":244,\"start\":0},\"textsStyle\":\" anf-ts-\n\ni\"}, {\"range\"™:{\"length\":244,\"start\":0},\"textStyle\":\"_anf-ts-1\"}],\"layout\":\"default-\nbody\", \"role\":\"body\", \"text\":\"The voluminous requests from Celgene became a rinse-and-\n\nrepeat cycle for many of the generic drug companies, according to court documents. Two\ncompanies, Lannett and Barr Laboratories, settled with Celgene. Mylande€™s suit will\n\nsoon head to trial.\",\"type\":\"text\"}, {\"identifier\":\" anf-body-\n47\",\"“inlineTextStyles\":[{\"range\": {\"length\":208, \"start\":0},\"textsStyle\":\" anf-ts-\n\ni\"}, {\"range\"™:{\"length\":208,\"start\":0},\"textStyle\":\" anf-ts-1\"}],\"layout\":\"default-—\nbody\", \"role\": \"body\", \"text\": \"aeeThis is really concerning conduct and Celgene is by far\n\nthe worst offender,d4€ Michael Carrier, a professor at Rutgers Law School who studies\npatent law, said of Celgenead€e™s tactics to delay generic\n\ndevelopment.\", \"type\": \"text\"}, {\"identifier\":\" anf-heading4-\n4\",\"layout\":\"heading4\", \"role\": \"heading4\",\"text\":\" Campaign attack ads over soaring drug\nprices\", \"type™:\"text\"}, {\"additions\"™: [{\"URL\":\"https://poll.qu.edu/new-jersey/releas\ndetail ?ReleaseID=2563\",\"range\":{\"length\":27,\"start\":160},\"type\":\"link\"}],\"identifier\":\"\n_anf-body-48\", \"inlineTextStyles\": [{\"range™: {\"length\":295,\"start\":0},\"textStyle\":\"_ anf-\nts-1\"},{\"range\"™:{\"length\":295,\"start\":0},\"textStyle\":\" anf-ts-1\"}],\"layout\":\"default-\nbody\", \"role\":\"body\", \"text\":\"As the Senate race careens toward the final weeks, the\nMenendez campaign has seen some troubling signs in recent polling. Despite maintaining\na six-point lead, a Quinnipiac poll in August found that 49 percent of New Jersey\nvoters believed that Mr. Menendez a€ewas involved in serious\n\nwrongdoing.a4€\", \"type\":\"text\"}, {\"additions\": [{\"URL\":\"https://www.youtube.com/watch?v=XE\nlizocN4sé&feature=youtu.be\", \"range\": {\"length\":21,\"start\":150},\"type™:\"Link\"}, {\"URL\":\"htt\n\nHOUSE_OVERSIGHT_028420",
  "metadata": {
    "original_filename": "IMAGES-009-HOUSE_OVERSIGHT_028420.txt",
    "source_dataset": "huggingface:tensonaut/EPSTEIN_FILES_20K",
    "character_count": 5314,
    "word_count": 519,
    "line_count": 93,
    "import_date": "2025-11-19T21:47:47.360602",
    "prefix": "IMAGES-009"
  }
}